Which lupus nephritis patients are at higher risk for CKD? #Abstract0624 shows coexisting tubulointerstitial inflammation/damage (TII/TID) on renal biopsy is linked to CKD progression (HR 2.667, 95% CI: 1.333-5.335) Risk high among Class III, IV, V and eGFR > 30 @RheumNow #ACR24

#0501 💥 JAKi & TNFi show faster short-term RA improvement (3months) compared to IL-6i & ABA ➡️n=9590(3049 JAKi, 4606 TNFi, 1284 IL-6, 651 ABA), 14 registers 🕒 JAKi, TNFi improved CDAI, pain, function in 1st two months then stabilised 💡Long-term data needed #ACR24 @RheumNow https://t.co/4yzeAAkGjq

• https://x.com/CaoilfhionnMD/status/1857806079457136834/photo/1

The rising placebo response rates in PsA trials are linked to global recruiting patterns, with more studies in less affluent countries. Limited access to healthcare may drive this trend, highlighting the need for awareness among stakeholders. Plenary Abstr#0722… https://t.co/FplpSlIamR https://t.co/NIp76IS6TZ

• https://x.com/i/web/status/1857805827815752105
• https://x.com/synovialjoints/status/1857805827815752105/photo/1

More evidence: persistence of imaging abnormalities is probably NOT an adequate metric of LVV tx failure Boiardi et al - 87% TAK/LV-GCA pt w persistent dz on imaging despite clinical remission, TAK>GCA PET avidity more persistent in GCA @RheumNow #ACR24 Abstract 1617

Which immunomodulators dampen recombinant zoster vaccine immunogenicity? In this 🇧🇷 study in autoimmune dx patients, overrepresented in non-responders are: - rituximab pts - 'combined therapy' strategies needed for them but reassuring for the others! #ACR24 ABST0248 @RheumNow https://t.co/he1ICa9WZg

• https://x.com/drdavidliew/status/1857804958550339997/photo/1

Kerschbaumer et al. Rising placebo rates in PsA RCTs appear linked to changes in global recruitment patterns. Dramatic relationship between GNI and placebo response rate. Crucial information for properly planning future trials @RheumNow #ACR24 Abstr#0772 https://t.co/PtHs2RXe0f https://t.co/OKG6czQrYD

• Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinic…
• https://x.com/RichardPAConway/status/1857804569620754475/photo/1

#Frailty leads to poor outcomes and occurs earlier in RA patients. Different tools measure frailty as a phenotype vs. deficit accumulation. Discover the role of frailty in ED from #LancetRheum Ageing Series by Drs. Sarah Lieber and @KWyshamMD ! #ACR24 @RheumNow ABST#1334 https://t.co/25XQBDQMCo

• https://x.com/JihaRheum/status/1857804066287460431/photo/1

Location of research matters Ab#0772 Global recruiting patterns impact PBO in PsA PBO results improve w time - 0.9%/year More globalization of trials w time Gross nation index (GNI) neg ass w ACR20 - inclusion of less affluent controls affects higher PBO response @RheumNow #ACR24

Poster#0035 🚨Postpartum RA Risk & Mucosal Immunity 👩‍🍼Elevated anti-CCP-IgG in cervicovaginal fluid of postpartum women (n=25) vs. controls. 🧪Local anti-CCP production despite negative serum ❓Childbirth-associated mucosal inflammation may drive RA onset. #ACR24 @RheumNow https://t.co/plvtyJDSY1

• https://x.com/CaoilfhionnMD/status/1857803562996117666/photo/1

To GLP or not to GLP—is it still even a question in obesity management given pluripotent benefits 👇🏻 Dr. Louis Aronne recommends ➡️ Start low and titrate slow 💊 ➡️ Provide pt education on GI side effects, ondansetron effective for nausea #ACR24 @RheumNow https://t.co/SzVg2dopCo

• https://x.com/CaoilfhionnMD/status/1857803392250241435/photo/1
• https://x.com/CaoilfhionnMD/status/1857803392250241435/photo/1

SELECT-GCA Trial results show UPA 15 mg + 26-week GC taper leads to 46% sustained remission vs. 29% with placebo + 52-week taper (P=.0019). UPA15 reduced GC use (median 1615mg vs. 2882mg, P<.0001) and improved fatigue scores. Key finding: UPA15 combined with a 26-week GC… https://t.co/rdHU3GuOwc https://t.co/oMS7x46sIB

• https://x.com/i/web/status/1857803311363002426
• https://x.com/synovialjoints/status/1857803311363002426/photo/1

Mycophenolate isn't great for vaccine immunogenicity, but withholding MMF for one week after both doses of recombinant zoster vaccine boosts Ab titres ++ in this Brazilian RCT. A week off post-vaccine: definitely worth considering in stable disease #ACR24 ABST0247 @RheumNow https://t.co/lajS5DzRbD

• https://x.com/drdavidliew/status/1857803007662157981/photo/1

CKD keeps a persistent low grade inflammatory state! Implications: CKD ⬆️risk for CV dz through different mech @RheumNow #ACR24 https://t.co/KcCvyTVaav

• https://x.com/KDAO2011/status/1857796055296856190/photo/1

Safety data reassuring with UPA 15 mg vs PBO No UPA MACE events, low VTE Ab#0770 @RheumNow #ACR24 https://t.co/lMf2dCz2RX https://t.co/3DnPIoVOt8

• https://x.com/ericdeinmd/status/1857795698420273349/photo/1
• https://twitter.com/ericdeinmd/status/1857794819352825977

Planned to post so much more from #ACR24; my favorite slides from today will have to suffice. From the #BCRC Dr Monica Guma’s - diet and microbiome. Dr @NamrataRheum -a reminder that we are all aging. Dr Connie Weyand’s -metabolic checkpoints in RA T cells and macrophage. https://t.co/MtsheVsUEQ

• https://x.com/kristenyoung/status/1857650141353898184/photo/1
• https://x.com/kristenyoung/status/1857650141353898184/photo/1
• https://x.com/kristenyoung/status/1857650141353898184/photo/1
• https://x.com/kristenyoung/status/1857650141353898184/photo/1